By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Next-generation sequencing technology firm GnuBio has completed its Series A equity financing round raising $8 million, which the company will use to accelerate the beta program for its platform.

The round had 12 participants, though company CEO John Boyce declined to identify them. GnuBio raised the first $3 million of the round in November and raised the remaining $5 million upon hitting certain milestones, he said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.